Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


175

projects in our pipeline

17

new molecular entities in our late-stage pipeline

1

new molecular entity approval



Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

Filter By:

Oncology (as of 12 November 2021)

Phase I

Phase I

  • AZD0466 haematological malignancies
  • AZD1390 glioblastoma
  • AZD2936 solid tumours
  • AZD4573 haematalogical malignancies
  • AZD5991 haematalogical malignancies
  • AZD7648 haematological and solid tumours
  • AZD7789 solid tumours
  • AZD8701 solid tumours
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + Koselugo solid tumours
  • IPH5201 solid tumours
  • MEDI1191 solid tumours
  • MEDI5752 + lenvatinib advanced renal cell carcinoma
  • MEDI9253 solid tumours
  • Tagrisso + (Koselugo or savolitinib) TATTON advanced EGFRm non-small cell lung cancer

Phase II

Phase II

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx) metastatic pancreatic cancer
  • adavosertib ovarian cancer, solid tumours, uterine serous cancer
  • AZD2811 nanoparticle solid tumours
  • AZD5305 solid tumours
  • camizestrant (AZD9833) estrogen receptor +ve breast cancer
  • capivasertib prostate cancer
  • ceralasertib solid tumours
  • Imfinzi (platform) COAST non small cell lung cancer
  • Imfinzi (platform) HUDSON post IO non-small cell lung cancer
  • Imfinzi (platform) NeoCOAST non-small cell lung cancer
  • Imfinzi + FOLFOX + bevacizumab COLUMBIA 1 1st-line metastatic microsatellite-stable colorectal cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + monalizumab solid tumours
  • MEDI5752 solid tumours
  • Post-1L Tagrisso ORCHARD (platform) EGFRm non-small cell lung cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer

Phase III

Phase III

  • camizestrant (AZD9833) + CDK4/6i SERENA-6 1L HR+ HER2- ESR1m breast cancer
  • camizestrant (AZD9833) + palbociclib SERENA-4 1st-line HR+ HER2- breast cancer
  • capivasertib + abiraterone CAPItello-281 PTEN deficient metastatic hormone sensitive prostate cancer
  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • capivasertib + fulvestrant CAPItello-291 2nd- line and beyond in AI resistant locally advanced (inoperable) or metastatic breast cancer
  • capivasertib + fulvestrant + palbociclib CAPItello-292 1st-line triplet in early relapse/ET resistant locally advanced (inoperable) or metastatic breast cancer
  • datopotamab deruxtecan TROPION-Lung01 2L+ NSCLC without actionable genomic mutations
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi +/- tremelimumab + CRT ADRIATIC 1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Koselugo/selumetinib SPRINT paediatric neurofibromatosis type-1
  • Lynparza + Imfinzi DuO-E 1st-line endometrial cancer
  • Lynparza + Imfinzi + bevacizumab DuO-O 1st-line ovarian cancer
  • monalizumab + cetuximab INTERLINK-1 2L+ relapsed metastatic head and neck squamous cell cancer
  • Orpathys (savolitinib) + Imfinzi SAMETA 1st-line papillary renal cell carcinoma

LCM Projects

LCM Projects

  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Calquence + R-CHOP ESCALADE 1st-line Diffuse Large B Cell Lymphoma
  • Calquence + venetoclax + obinutuzumab AMPLIFY 1st-line chronic lymphocytic leukaemia
  • Enhertu DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • Enhertu DESTINY-Breast05 HER2-positive post-neoadjuvant high-risk breast cancer
  • Enhertu DESTINY-Breast06 post-ET HER2low/HR+ breast cancer 2L
  • Enhertu DESTINY-Breast09 1st line HER2-postitive breast cancer
  • Enhertu DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • Enhertu DESTINY-Gastric04 2nd-line HER2-positive gastric
  • Enhertu DESTINY-Lung01 HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer
  • Enhertu DESTINY-PanTumour01 HER2-expressing solid tumors
  • Enhertu DESTINY-PanTumour02 HER2-expressing solid tumors
  • Enhertu DESTINY-Breast02 HER2-positive, unresectable and/or metastatic breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
  • Enhertu DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • Enhertu (platform) DESTINY-Breast07 HER2+ breast cancer
  • Enhertu (platform) DESTINY-Breast08 HER2low breast cancer
  • Imfinzi CALLA locally-advanced cervical cancer
  • Imfinzi MERMAID-2 stage II-III premetastatic NSCLC
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PEARL 1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CRT KUNLUN locally advanced esophageal squamous cell carcinoma
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CTx MERMAID-1 stage II-III adjuvant NSCLC
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage II-III) non-small cell lung cancer
  • Imfinzi + EV +- treme VOLGA muscle invasive bladder cancer
  • Imfinzi + FLOT MATTERHORN Neo-adjuvant/adjuvant gastric cancer
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellular carcinoma
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellular carcinoma
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Lynparza LYNK-003 platinum sensitive 1st-line colorectal cancer
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Lynparza# MONO-OLA1 1st-line BRCAwt ovarian cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage III EGFRm non-small cell lung cancer
  • Tagrisso + CTx FLAURA2 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso +/- CTx neoadjuvant NeoADAURA stage II/III resectable EGFRm NSCLC

Cardiovascular, Renal & Metabolism (as of 12 November 2021)

Phase I

Phase I

  • AZD2373 nephropathy
  • AZD2693 NASH
  • AZD3366 cardiovascular disease
  • AZD3427 cardiovascular disease
  • AZD5462 cardiovascular disease
  • MEDI8367 chronic kidney disease

Phase II

Phase II

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease / chronic kidney disease
  • AZD8233 cardiovascular disease
  • AZD8601 cardiovascular disease
  • AZD9977 + Farxiga/Forxiga heart failure with CKD
  • cotadutide type-2 diabetes, obesity and NASH, diabetic kidney disease
  • MEDI5884 cardiovascular disease
  • MEDI6570 cardiovascular disease
  • tozorakimab (MEDI3506) diabetic kidney disease
  • zibotentan + Farxiga/Forxiga ZENITH-CKD chronic kidney disease

Phase III

Phase III

  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

LCM Projects

  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Farxiga/Forxiga DAPA-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga DAPA-MI Prevention of heart failure and CV death following a myocardial infarction
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Lokelma DIALIZE-Outcomes CV outcomes in patients on chronic haemodialysis with hyperkalaemia
  • Lokelma STABILIZE-CKD hyperkalaemia in CKD
  • roxadustat anaemia in myelodysplastic syndrome
  • roxadustat chemotherapy induced anaemia
  • Xigduo XR/Xigduo type-2 diabetes

Respiratory & Immunology (as of 12 November 2021)

Phase I

Phase I

  • AZD0284 psoriasis/respiratory
  • AZD0449 asthma
  • AZD4604 asthma

Phase II

Phase II

  • AZD1402 asthma
  • AZD7986 chronic obstructive pulmonary disease
  • brazikumab EXPEDITION ulcerative colitis
  • navafenterol chronic obstructive pulmonary disease
  • Saphnelo (anifrolumab) lupus nephritis
  • tezepelumab chronic obstructive pulmonary disease
  • tozorakimab (MEDI3506) COPD/atopic dermatitis/asthma/COVID-19

Phase III

Phase III

  • AZD2816 (next generation COVID-19 vaccine) prevention of COVID-19
  • AZD7442 prevention and treatment of COVID-19
  • brazikumab INTREPID crohn's disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • nirsevimab passive RSV immunisation
  • PT027 asthma
  • Saphnelo (anifrolumab) systemic lupus erythematosus (subcutaneous)
  • Saphnelo (anifrolumab) TULIP 1 & TULIP 2 systemic lupus erythematosus
  • tezepelumab NAVIGATOR severe uncontrolled asthma
  • tezepelumab WAYPOINT nasal polyps
  • Vaxzevia / COVID-19 Vaccine AstraZeneca COVID vaccine

LCM Projects

LCM Projects

  • Breztri/Trixeo (PT010) KALOS LAGOS asthma
  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra ARROYO chronic spontaneous urticaria
  • Fasenra FJORD bullous pemphigoid
  • Fasenra HILLIER atopic dermatitis
  • Fasenra MAHALE non-cystic fibrosis bronchiectasis
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra MESSINA eosinophilic esophagitis
  • Fasenra NATRON hypereosinophilic syndrome
  • Fasenra OSTRO ORCHID (China/Japan) nasal polyps
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma

Rare Disease (as of 12 November 2021)

Phase I

Phase I

  • ALXN1720 Generalised Myasthenia Gravis
  • ALXN1820 Haematology
  • ALXN1850 Subcutaneous next generation asfotase alfa for Hypophosphatasia

Phase II

Phase II

  • ALXN2050 Paroxysmal Nocturnal Hemoglobinuria
  • danicopan (ALXN2040) Geographic atrophy

Phase III

Phase III

  • acoramidis (ALXN2060) Oral TTR stabilizer for Transthyretin Amyloid Cardiomyopathy
  • ALXN1840 Oral copper chelator Wilson's disease
  • CAEL-101 AL amyloidosis
  • danicopan (ALXN2040) Paroxysmal Nocturnal Hemoglobinuria-Extravascular Hemolysis

LCM Projects

LCM Projects

  • ALXN1830 Warm Autoimmune Hemolytic anemia
  • Andexxa (ALXN2070) Acute Major Bleed
  • Andexxa (ALXN2070) Urgent Surgery
  • Ultomiris (ALXN1210) Complement-Mediated Thrombotic Microangiopathy
  • Ultomiris (ALXN1210) Generalised Myasthenia Gravis
  • Ultomiris (ALXN1210) Hematopoietic Stem Cell Transplant–associated Thrombotic Microangiopathy
  • Ultomiris (ALXN1210) Neuromyelitis Optica Spectrum Disorder
  • Ultomiris (ALXN1210) Subcutaneous administration Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome

Other (as of 12 November 2021)

Phase I

Phase I

  • AZD4041 opioid use disorder
  • MEDI0618 osteoarthritis pain
  • MEDI1341 parkinson's disease
  • MEDI1814 alzheimer’s disease

Phase II

Phase II

  • MEDI7352 osteoarthritis pain and painful diabetic neuropathy
  • suvratoxumab prevention of nosocomial Staphylococcus aureus pneumonia

Phase III

Phase III

LCM Projects

LCM Projects

Removed since last quarter